Macular Edema News and Research RSS Feed - Macular Edema News and Research

Hercules Technology Growth Capital issues advance payment to Alimera Sciences

Hercules Technology Growth Capital issues advance payment to Alimera Sciences

Alimera Sciences, Inc. (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has received a $25 million advance from Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules). [More]
Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). [More]
EYLEA Injection gets approval in Japan for treatment of myopic CNV

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV). [More]
FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). [More]
New way to reduce abnormal blood vessel growth and leakage in eye

New way to reduce abnormal blood vessel growth and leakage in eye

Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development of new drugs for wet macular degeneration and diabetic macular edema. [More]
iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
Research demonstrates that African Americans bear heavier burden of DME

Research demonstrates that African Americans bear heavier burden of DME

Research by Keck Medicine of USC ophthalmology scientists demonstrates that African Americans bear heavier burden of diabetic macular edema (DME), one of the leading causes of blindness in diabetic patients in the United States. [More]
KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. [More]

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc., today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. [More]
Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy. [More]
European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema. [More]
FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]
Iodine supplement can reduce central foveal swelling in RP patients with CME

Iodine supplement can reduce central foveal swelling in RP patients with CME

Cystoid macular edema (CME) is a common complication of retinitis pigmentosa (RP), a family of retinal diseases in which patients typically lose night and side vision first and then develop impaired central vision. CME can also decrease central vision. [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]
Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. [More]
Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO). [More]
Medicare to pay for hep C screenings for baby boomers

Medicare to pay for hep C screenings for baby boomers

The decision comes amid controversy surrounding the costs of new drugs to treat the blood-borne virus. Meanwhile, two studies find that Medicare could save billions if doctors switched from an expensive eye medication to a similar, much cheaper one and, also, if Part D plans were selected based on the actual drugs patients take. [More]
First Edition: June 3, 2014

First Edition: June 3, 2014

Today's headlines include coverage of Medicare data released Monday indicating that 2012 charges for some common inpatient hospital procedures dramatically increased over the previous year. [More]
ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST). [More]